Barclays Maintains Overweight on LifeStance Health Gr, Raises Price Target to $13
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Peter Warendorf maintains LifeStance Health Gr (NASDAQ:LFST) with a Overweight and raises the price target from $9 to $13.
Barclays analyst Peter Warendorf maintains LifeStance Health Gr (NASDAQ:LFST) with a Overweight and raises the price target from $9 to $13.